Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01616654 · ClinicalTrials.gov registry record · Phase 2
Dose Range Study of CD5789 in Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 304
- Enrollment target
- 20
- Study locations
NCT01616654 is a Phase 2 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 304 participants, above the 271-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT01616654, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 304 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
Conditions Studied
Interventions
- DRUG Vehicle cream
- DRUG CD5789 25 µg/g cream
- DRUG CD5789 50 µg/g cream
- DRUG CD5789 100 µg/g cream
- DRUG Tazarotene 0.1% gel
Study Locations (20)
California
- Parexel Early Phase - Glendale
- Odyssey Medispa - Marina del Rey
- Rady Children's Hospital - San Diego
Florida
- FXM Research Corp Miami - Miami
- FMX Research Miramar - Miramar
Michigan
- Hamzavi Dermatology - Fort Gratiot
- Somerset Skin Centre - Troy
North Carolina
- Zoe Drealos, MD - High Point
- PMG Research of Wilmington - Wilmington
Texas
- Arlington Center for Dermatology - Arlington
- Suzanne Bruce and Associates P.A. The Center for Skin Research - Houston
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
Georgia
- Meda Phase, Inc - Newnan
Indiana
- Deaconess Clinic, Inc. - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2012-06-20 |
| Est. Completion | 2014-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01616654
The ClinicalTrials.gov registry entry for NCT01616654 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 271-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (12% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 5 interventions - of which Vehicle cream is the first listed.
NCT01616654 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT01616654 about?
NCT01616654 is a clinical study titled "Dose Range Study of CD5789 in Acne Vulgaris". To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
What is the current status of trial NCT01616654?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 304 participants. The study started on 2012-06-20. Estimated completion is 2014-06-12.
What conditions does trial NCT01616654 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT01616654?
The interventions under investigation include: Vehicle cream (DRUG), CD5789 25 µg/g cream (DRUG), CD5789 50 µg/g cream (DRUG), CD5789 100 µg/g cream (DRUG), Tazarotene 0.1% gel (DRUG).
Who is sponsoring clinical trial NCT01616654?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01616654 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.